UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

Cytotherapy (Oxford, England), 2017-02, Vol.19 (2), p.235-249

2017

Link zum Volltext

Verfügbarkeit prüfen

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

EMBO molecular medicine, 2018-11, Vol.10 (11), p.n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

Frontiers in immunology, 2020-10, Vol.11, p.581468-581468

2020

Link zum Volltext

Verfügbarkeit prüfen

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.411-423

2008

Link zum Volltext

Verfügbarkeit prüfen

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

The Journal of clinical investigation, 2016-08, Vol.126 (8), p.3036-3052

2016

Link zum Volltext

Verfügbarkeit prüfen

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

Cancer Immunology, Immunotherapy, 2012-09, Vol.61 (9), p.1451-1461

2012

Link zum Volltext

Verfügbarkeit prüfen

"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

Scientific reports, 2020-02, Vol.10 (1), p.2141-2141, Article 2141

2020

Link zum Volltext

Verfügbarkeit prüfen

Chimeric antigen receptor‐engineered cytokine‐induced killer cells overcome treatment resistance of pre‐B‐cell acute lymphoblastic leukemia and enhance survival

International journal of cancer, 2016-10, Vol.139 (8), p.1799-1809

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Molecular therapy, 2009-10, Vol.17 (10), p.1779-1787

2009

Link zum Volltext

Verfügbarkeit prüfen

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

Cancer Immunology, Immunotherapy, 2015-05, Vol.64 (5), p.621-634

2015

Link zum Volltext

Verfügbarkeit prüfen

T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing

Blood, 2012-11, Vol.120 (22), p.4334-4342

2012

Link zum Volltext

Verfügbarkeit prüfen

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Nuclear medicine and biology, 2008-07, Vol.35 (5), p.579-588

2008

Link zum Volltext

Verfügbarkeit prüfen

Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity

The Journal of immunology (1950), 2005-05, Vol.174 (9), p.5481-5489

2005

Link zum Volltext

Verfügbarkeit prüfen

Liposome-based Systems for Anti-tumor Vaccination: Influence of Lipopeptide Adjuvants

Journal of liposome research, 2006-01, Vol.16 (3), p.205-213

2006

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic antibodies

Current molecular medicine, 2004-08, Vol.4 (5), p.539

2004

Link zum Volltext

Verfügbarkeit prüfen

Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor

Oncogene, 2003-03, Vol.22 (10), p.1557-1567

2003

Link zum Volltext

Verfügbarkeit prüfen

Functional Properties of a Monoclonal Antibody Inhibiting the Hepatitis C Virus RNA-dependent RNA Polymerase

The Journal of biological chemistry, 2002-01, Vol.277 (1), p.593-601

2002

Link zum Volltext

Verfügbarkeit prüfen

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

International journal of cancer, 2000-04, Vol.86 (2), p.269-275

2000

Link zum Volltext

Verfügbarkeit prüfen

Intracellular expression of single chain antibodies reverts ErbB-2 transformation

The Journal of biological chemistry, 1994-09, Vol.269 (39), p.23931-23936

1994

Link zum Volltext

Verfügbarkeit prüfen

Construction and Characterization of Bispecific Costimulatory Molecules Containing a Minimized CD86 (B7-2) Domain and Single-Chain Antibody Fragments for Tumor Targeting

Clinical cancer research, 2000-11, Vol.6 (11), p.4314-4322

2000

Link zum Volltext

Verfügbarkeit prüfen

Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor

Cancer research (Chicago, Ill.), 1992-11, Vol.52 (22), p.6310-6317

1992

Link zum Volltext

Verfügbarkeit prüfen

Generation and Characterization of Recombinant Vascular Targeting Agents from Hybridoma Cell Lines

BioTechniques, 2001-01, Vol.30 (1), p.190-200

2001

Link zum Volltext

Verfügbarkeit prüfen

Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene

The Journal of immunology (1950), 1997-05, Vol.158 (10), p.4584

1997

Link zum Volltext

Verfügbarkeit prüfen

Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4

FEBS letters, 1997-04, Vol.407 (1), p.63-68

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaTumors

ThemaMice

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(38)

Sprache

Englisch
(38)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

In vivo generation of human CD19‐CAR T cells results in B‐cell depletion and signs of cytokine release syndrome

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

"UniCAR"-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

Chimeric antigen receptor‐engineered cytokine‐induced killer cells overcome treatment resistance of pre‐B‐cell acute lymphoblastic leukemia and enhance survival

Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

T-cell receptor gene transfer exclusively to human CD8+ cells enhances tumor cell killing

Tracking of [18 F]FDG-labeled natural killer cells to HER2/neu-positive tumors

Targeted Delivery of the ErbB2/HER2 Tumor Antigen to Professional APCs Results in Effective Antitumor Immunity

Mitophagy in Intestinal Epithelial Cells Triggers Adaptive Immunity during Tumorigenesis

Liposome-based Systems for Anti-tumor Vaccination: Influence of Lipopeptide Adjuvants

Therapeutic antibodies

Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor

Functional Properties of a Monoclonal Antibody Inhibiting the Hepatitis C Virus RNA-dependent RNA Polymerase

Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

Intracellular expression of single chain antibodies reverts ErbB-2 transformation

Construction and Characterization of Bispecific Costimulatory Molecules Containing a Minimized CD86 (B7-2) Domain and Single-Chain Antibody Fragments for Tumor Targeting

Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor

Generation and Characterization of Recombinant Vascular Targeting Agents from Hybridoma Cell Lines

Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene

Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4

Aktive Filter

Suchergebnisse filtern